title: Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences.
abstract: The provision of stress ulcer prophylaxis (SUP) for the prevention of clinically significant bleeding is widely recognized as a crucial component of care in critically ill patients. Nevertheless, SUP is often provided to non-critically ill patients despite a risk for clinically significant bleeding of roughly 0.1 %. The overuse of SUP therefore introduces added risks for adverse drug events and cost, with minimal expected benefit in clinical outcome. Historically, histamine-2-receptor antagonists (H2RAs) have been the preferred agent for SUP; however, recent data have revealed proton pump inhibitors (PPIs) as the most common modality (76 %). There are no high quality randomized controlled trials demonstrating superiority with PPIs compared with H2RAs for the prevention of clinically significant bleeding associated with stress ulcers. In contrast, PPIs have recently been linked to several adverse effects including Clostridium difficile diarrhea and pneumonia. These complications have substantial economic consequences and have a marked impact on the overall cost effectiveness of PPI therapy. Nevertheless, PPI use remains widespread in patients who are at both high and low risk for clinically significant bleeding. This article will describe the utilization of PPIs for SUP and present the clinical and economic consequences linked to their use/overuse.
authors.affiliation: Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N 59th Avenue, Glendale, AZ, 85308, USA, jbarle@midwestern.edu.
authors.forename: Jeffrey F
authors.initials: JF
authors.lastname: Barletta
authors.forename: David A
authors.initials: DA
authors.lastname: Sclar
mesh_terms: D003362:Cost-Benefit Analysis; D004363:Drug Utilization / Q000191:economics* / Q000639:trends; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D010437:Peptic Ulcer / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D010438:Peptic Ulcer Hemorrhage / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D013315:Stress, Psychological / Q000150:complications* / Q000191:economics
chemical_list: D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors